Related Experiment Video
Updated: Jul 18, 2025
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
Aggregation-Inhibiting scFv-Based Therapies Protect Mice against AAV1/2-Induced A53T-α-Synuclein Overexpression
Benjamin W Schlichtmann1,2, Bharathi N Palanisamy3, Emir Malovic3
1Department of Chemical and Biological Engineering, Iowa State University, Ames, IA 50011, USA.
Abstract:
To date, there is no cure for Parkinson's disease (PD). There is a pressing need for anti-neurodegenerative therapeutics that can slow or halt PD progression by targeting underlying disease mechanisms. Specifically, preventing the build-up of alpha-synuclein (αSyn) and its aggregated and mutated forms is a key therapeutic target. In this study, an adeno-associated viral vector loaded with the A53T gene mutation was used to induce rapid αSyn-associated PD pathogenesis in C57BL/6 mice. We tested the ability of a novel therapeutic, a single chain fragment variable (scFv) antibody with specificity only for pathologic forms of αSyn, to protect against αSyn-induced neurodegeneration, after unilateral viral vector injection in the substantia nigra. Additionally, polyanhydride nanoparticles, which provide sustained release of therapeutics with dose-sparing properties, were used as a delivery platform for the scFv. Through bi-weekly behavioral assessments and across multiple post-mortem immunochemical analyses, we found that the scFv-based therapies allowed the mice to recover motor activity and reduce overall αSyn expression in the substantia nigra. In summary, these novel scFv-based therapies, which are specific exclusively for pathological aggregates of αSyn, show early promise in blocking PD progression in a surrogate mouse PD model.
Insights
Researchers developed a novel antibody therapy targeting alpha-synuclein (αSyn) aggregates to combat Parkinson's disease (PD). This promising treatment demonstrated motor function recovery and reduced αSyn in a mouse model, offering hope for slowing PD progression.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Parkinson's disease (PD) lacks a cure, necessitating treatments to slow neurodegeneration.
- Alpha-synuclein (αSyn) aggregation is a key pathological hallmark and therapeutic target in PD.
- Novel therapeutics are needed to specifically target and reduce pathological αSyn.
Purpose of the Study:
- To evaluate a novel single chain fragment variable (scFv) antibody targeting pathologic alpha-synuclein (αSyn) for Parkinson's disease (PD).
- To assess the efficacy of scFv-based therapy delivered via nanoparticles in a mouse model of PD.
- To investigate the potential of blocking PD progression by targeting αSyn aggregates.
Main Methods:
- Induced PD pathogenesis in C57BL/6 mice using an adeno-associated viral vector with the A53T αSyn gene mutation.
- Administered a novel scFv antibody, specific for pathologic αSyn, encapsulated in polyanhydride nanoparticles for sustained release.
- Conducted bi-weekly behavioral assessments and post-mortem immunochemical analyses to evaluate therapeutic effects.
Main Results:
- Mice treated with scFv-based therapy showed recovery of motor activity.
- Therapy led to a reduction in overall alpha-synuclein (αSyn) expression in the substantia nigra.
- The scFv antibody demonstrated specificity for pathological αSyn aggregates.
Conclusions:
- Novel scFv-based therapies targeting pathological alpha-synuclein (αSyn) show promise in a mouse model of Parkinson's disease (PD).
- Sustained delivery of scFv antibodies via nanoparticles can mitigate PD-related neurodegeneration.
- These findings support the potential of scFv therapeutics for halting PD progression by targeting αSyn.
More Related Videos
08:33Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
Published on: February 28, 2016
05:55Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
Published on: October 3, 2011